Short-Course Steroids Trigger HBV Reactivation in COVID-19
Analysis Gastroenterology / Hepatology Hypothesis-generating Grade: Very Low
Öztürk Çerik H, Aldemir Ö, Katirci B, et al.
Sep 1, 2026 · Published in: Medicine
Screen for HBV before giving corticosteroids to COVID-19 patients.
Adding Camrelizumab to TACE Plus Donafenib in PVTT-Positive HCC
Analysis Gastroenterology / Hepatology Hypothesis-generating Grade: Low
Zhang Q, Qing H, Lei Z, et al.
Aug 20, 2026 · Published in: Frontiers in Immunology
Transarterial chemoembolization with donafenib and camrelizumab may extend survival in challenging liver cancer cases.
Rifaximin in Pediatric Hepatic Encephalopathy: First Trial, Ammonia Miss
Analysis Gastroenterology / Hepatology Hypothesis-generating Grade: Low
Okajima H, Tagawa M, Fujisawa M, et al.
Jul 22, 2026 · Published in: Hepatology Communications
Rifaximin shows promise in pediatric hepatic encephalopathy treatment.
Ustekinumab Salvages Pediatric IBD After Anti-TNF Failure
Analysis Gastroenterology / Hepatology Hypothesis-generating Grade: Low
Heng Z, Zhan L, Zhang Y, et al.
Jul 20, 2026 · Published in: BMC Gastroenterology
Could ustekinumab be the answer for pediatric IBD post-anti-TNF failure?
Fibrosis-Directed MASH Therapeutics Enter the Approved-Drug Era
Analysis Gastroenterology / Hepatology Confirmatory Grade: Low
Li F, Li H, Juramt D, et al.
Jul 2, 2026 · Published in: BMJ Open Gastroenterology
MASLD leads global liver disease, now with targeted therapies emerging.
Mirikizumab sustains multidomain UC remission through four years
Analysis Gastroenterology / Hepatology Confirmatory Grade: Low
Sands BE, Clemow DB, D'Haens G, et al.
Jun 1, 2026 · Published in: Inflammatory Bowel Diseases
Four-year study shows lasting ulcerative colitis remission with mirikizumab.
AASLD Adds Semaglutide to MASH Practice Guidance With NIT-Based Selection
Guideline Gastroenterology / Hepatology Practice-changing Grade: Moderate
Bansal MB, Patton H, Morgan TR, et al.
May 1, 2026 · Published in: Hepatology (Baltimore, Md.)
Semaglutide offers new hope for MASH management with significant fibrosis improvement.
Resmetirom Update: Positioning the First Approved MASH Therapy
Analysis Gastroenterology / Hepatology Confirmatory Grade: Moderate
Van Kleef LA, Michel M, Alkhouri N, et al.
Jan 1, 2026 · Published in: Drug Design, Development and Therapy
Resmetirom is the first drug to reverse MASH and fibrosis.
Resmetirom Efficacy Holds With GLP-1 or SGLT2 Background; Weight Loss Amplifies It
Analysis Gastroenterology / Hepatology Confirmatory Grade: Moderate
Noureddin M, Rinella M, Taub R, et al.
Dec 1, 2025 · Published in: Alimentary Pharmacology & Therapeutics
Resmetirom shows promise in MASH, especially with weight loss.
EASL-EASD-EASO Guidelines Redefine MASLD Care With Resmetirom Entry
Guideline Gastroenterology / Hepatology Practice-changing Grade: Moderate
European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO)
Sep 1, 2024 · Published in: Journal of Hepatology
New guidelines transform MASLD management with non-invasive testing and targeted therapies.
Survodutide Improves MASH Histology Across Doses in Phase 2
Analysis Gastroenterology / Hepatology Hypothesis-generating Grade: Moderate
Sanyal AJ, Bedossa P, Fraessdorf M, et al.
Jul 25, 2024 · Published in: The New England Journal of Medicine
Survodutide shows promise in treating MASH without worsening fibrosis.
Tirzepatide Resolves MASH but Fibrosis Benefit Remains Unproven
Analysis Gastroenterology / Hepatology Hypothesis-generating Grade: Moderate
Loomba R, Hartman ML, Lawitz EJ, et al.
Jul 25, 2024 · Published in: The New England Journal of Medicine
Tirzepatide offers potential new hope for MASH management.